Literature DB >> 12616448

Immune responses in hepatitis B virus infection.

Barbara Rehermann1.   

Abstract

Hepatitis B virus infection is one of the most frequent causes of chronic liver disease worldwide. Even though a preventive vaccine is available, the search for a cure for chronically infected patients remains a high priority to reduce the morbidity and mortality from liver cirrhosis and hepatocellular carcinoma. This review summarizes the immune response in acute, self-limited and chronic hepatitis B; its differential effects on viral replication and liver injury; and prospects for immunotherapy.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12616448     DOI： 10.1055/s-2003-37586

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN： 0272-8087            Impact factor:   6.115


  28 in total

Review 1.  Hepatitis B virus-induced oncogenesis.

Authors:  Joachim Lupberger; Eberhard Hildt
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

2.  Hepatitis associated with aplastic anemia: do CD8(+) kupffer cells have a role in the pathogenesis?

Authors:  Cem Cengiz; Nesrin Turhan; O Faruk Yolcu; Sevinc Yilmaz
Journal:  Dig Dis Sci       Date:  2007-04-19       Impact factor: 3.199

Review 3.  The underlying mechanisms for the "simultaneous HBsAg and anti-HBs serological profile".

Authors:  R A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-12       Impact factor: 3.267

4.  Frequency of HIV and HCV Co-Infections in Chronic HBV Patients Referred to Taleghani Hospital, Tehran, Iran from 2006 to 2010.

Authors:  Seyed Mohammad Ebrahim Tahaei; Seyed Reza Mohebbi; Pedram Azimzadeh; Mohsen Vahedi; Shohreh Almasi; Sara Romani; Afsaneh Sharifian; Faramarz Derakhshan; Mohammad Reza Zali
Journal:  Hepat Mon       Date:  2011-12-20       Impact factor: 0.660

5.  Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort.

Authors:  H Nina Kim; Carla V Rodriguez; Stephen Van Rompaey; Joseph J Eron; Chloe L Thio; Heidi M Crane; Edgar T Overton; Michael S Saag; Jeffrey Martin; Elvin Geng; Michael Mugavero; Benigno Rodriguez; W Christopher Mathews; Stephen Boswell; Richard Moore; Mari M Kitahata
Journal:  J Acquir Immune Defic Syndr       Date:  2014-05-01       Impact factor: 3.731

6.  Association of TNF-α Promoter Polymorphism with HBV Associated Disease Outcome Among HBV Infected Patients from Orissa, Southern Part of East India.

Authors:  Rajesh Panigrahi; Neelakshi Sarkar; Avik Biswas; Ananya Pal; Debraj Saha; Shivaram P Singh; Manas K Panigrahi; Manikanana Bandopadhyay; Sekhar Chakrabarti; Runu Chakravarty
Journal:  J Clin Exp Hepatol       Date:  2014-09-18

7.  Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model.

Authors:  Jun Wu; Shunmei Huang; Xiaoli Zhao; Mingfa Chen; Yong Lin; Youchen Xia; Chan Sun; Xuecheng Yang; Junzhong Wang; Yan Guo; Jingjiao Song; Ejuan Zhang; Baoju Wang; Xin Zheng; Joerg F Schlaak; Mengji Lu; Dongliang Yang
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

8.  Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B.

Authors:  Rong-Nan Chien
Journal:  Hepatol Int       Date:  2008-04-10       Impact factor: 6.047

9.  CCR5, MCP-1 and VDR Gene Polymorphisms Are Associated with the Susceptibility to HBV Infection.

Authors:  Bita Moudi; Zahra Heidari; Hamidreza Mahmoudzadeh-Sagheb
Journal:  Indian J Clin Biochem       Date:  2018-06-27

10.  HBV replication is significantly reduced by IL-6.

Authors:  Tzer-Min Kuo; Cheng-Po Hu; Ya-Ling Chen; Ming-Hsiang Hong; King-Song Jeng; Chun-Chin T Liang; Mong-Liang Chen; Chungming Chang
Journal:  J Biomed Sci       Date:  2009-04-20       Impact factor: 8.410
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.